The many faces of interleukin‐6: the role of IL‐6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis

TC Barnes, ME Anderson… - International journal of …, 2011 - Wiley Online Library
Interleukin‐6 is currently attracting significant interest as a potential therapeutic target in
systemic sclerosis (SSc). In this paper, the biology of interleukin‐6 is reviewed, and the …

The roles of immune cells in the pathogenesis of fibrosis

E Huang, N Peng, F Xiao, D Hu, X Wang… - International journal of …, 2020 - mdpi.com
Tissue injury and inflammatory response trigger the development of fibrosis in various
diseases. It has been recognized that both innate and adaptive immune cells are important …

Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial

G Sircar, RP Goswami, D Sircar, A Ghosh… - Rheumatology, 2018 - academic.oup.com
Objectives SSc is characterized by fibrotic changes in the skin and lung, and the mainstay of
treatment has been CYC. B cell involvement suggests that rituximab (RTX) may also be of …

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

M Elhai, M Boubaya, O Distler, V Smith… - Annals of the …, 2019 - ard.bmj.com
Objective To assess the safety and efficacy of rituximab in systemic sclerosis (SSc) in clinical
practice. Methods We performed a prospective study including patients with SSc from the …

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

S Jordan, JHW Distler, B Maurer, D Huscher… - Annals of the …, 2015 - ard.bmj.com
Objectives To assess the effects of Rituximab (RTX) on skin and lung fibrosis in patients with
systemic sclerosis (SSc) belonging to the European Scleroderma Trial and Research …

A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease

D Daoussis, K Melissaropoulos… - Seminars in arthritis and …, 2017 - Elsevier
Objectives Rituximab (RTX) may favorably affect lung function and skin fibrosis in patients
with systemic sclerosis (SSc). We aimed to assess long-term efficacy and safety of RTX in …

Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis

A De Lauretis, P Sestini, P Pantelidis… - The Journal of …, 2013 - jrheum.org
Objective. Biomarkers of progression of interstitial lung disease (ILD) are needed to allow
early therapeutic intervention in patients with scleroderma-associated disease (SSc-ILD) …

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised …

P Saunders, V Tsipouri, GJ Keir, D Ashby, MD Flather… - Trials, 2017 - Springer
Background Interstitial lung disease (ILD) frequently complicates systemic autoimmune
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …

Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature

D Giuggioli, F Lumetti, M Colaci, P Fallahi… - Autoimmunity …, 2015 - Elsevier
Background The treatment of systemic sclerosis (SSc) represents a great clinical challenge
because of the complex disease pathogenesis including vascular, fibrotic, and immune T …

BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance

T Matsushita, T Kobayashi, K Mizumaki, M Kano… - Science …, 2018 - science.org
Systemic sclerosis (SSc) is an autoimmune disease characterized by skin and lung fibrosis.
More than 90% of patients with SSc are positive for autoantibodies. In addition, serum B cell …